CommercialPrior AuthMedium impact
State and School Employees' Health Insurance Plan - Lysosomal Storage Disorders
Blue Cross & Blue Shield of Mississippi·MS · Endocrinology, Hematology, Pediatrics·Medical Policy
We identified it
Jun 20, 2026
Summary
This is a new comprehensive policy for State and School Employees' Health Insurance Plan covering enzyme replacement therapies for lysosomal storage disorders including Gaucher disease, mucopolysaccharidosis, and Fabry disease. The policy establishes detailed prior authorization criteria, age requirements, diagnostic testing requirements, and renewal criteria for 12 different specialized enzyme therapies.
Action Required
Immediately: Billing team must implement prior authorization requirements for all lysosomal storage disorder enzyme therapies (Aldurazyme, Cerezyme, Elaprase, Elelyso, Elfabrio, Fabrazyme, Kanuma, Lumizyme, Naglazyme, Nexviazyme, Pombiliti, Vpriv) for State and School Employee Health Plan members. Update system to flag these high-cost specialty drugs for prior auth review. Providers must document specialist consultation, specific diagnostic test results, and clinical criteria before treatment initiation. Claims without proper authorization will be denied.